Companies › Healthgen Biotechnology
3 active drug programs in 3 registered trials: 3 Phase 2; Gastroenterology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Dimethicone emulsion Antifoaming agent; reduces gastric foam to improve mucosal visibility | – | Phase 2 | Gastric Mucosal Lesion | – |
| OsrHSA Recombinant human serum albumin expressed in rice plants (Oryza sativa) | – | Phase 2 | Cirrhotic Ascites | – |
| Recombinant Human Chymotrypsin (OsrhCT) Serine protease; mucolytic enzyme to improve gastric mucosa visualization | CTRL | Phase 2 | Gastric Mucosal Lesion | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04835480 | OsrHSA | Phase 2 | Cirrhotic Ascites | Gastroenterology | Jun 2022 |
| NCT06722664 | Recombinant Human Chymotrypsin (OsrhCT) | Phase 2 | Gastric Mucosal Lesion | Gastroenterology | May 2025 |
| NCT06722664 | Dimethicone emulsion | Phase 2 | Gastric Mucosal Lesion | Gastroenterology | May 2025 |
–
NorthSea Therapeutics TRYP Therapeutics Dr. Falk Pharma Napo Therapeutics Panafina
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.